New Phase Ltd

Oncohost Ltd.

Technion Research & Development Foundation Ltd

Ella Fremder

Yuval Shaked

Eyal Jacob

Raphael Hof

Raz Khandadash

Ami Aronheim

Provided are blocking agents to IL-1α, IL-1β, or IL-1R activity for use in combination with radiotherapy for treating cancer patients in which radiotherapy treatment induces IL-1α, IL-1β or both in their circulation.

Cancer treatment by blocking host-induced IL-1 in combination with radiotherapy

Provided are blocking agents to IL-1&#x3b1;, IL-1&#x3b2;, or IL-1R activity for use in combination with radiotherapy for treating cancer patients in which radiotherapy treatment induces IL-1&#x3b1;, IL-1&#x3b2; or both in their circulation.

A method for treating cancer and/or preventing or reducing metastasis or treating angiogenesis related disorders comprising the step of administering IL-31 or peptide which is at least about 70%, homologous to the IL-31 sequence as set forth in SEQ ID No. 1.

Method of treating cancer with compositions comprising IL-31

Apparatus and methods are described for use with a subject suffering from cancer. A nanoparticle () includes an inner core () that comprises a phase-change material that is configured to absorb latent heat of fusion by undergoing a phase change. An outer layer () disposed around the inner core includes a plurality of nano-spheres () of at least one metal, and a plurality of molecules () of a substance that binds preferentially with cancerous cells relative to non-cancerous cells. The nanoparticle has a volume of at least 65,000 nmand is elongatable into an ellipsoid, such that, when the nanoparticle is maximally elongated, each of the semi-axes defined by the ellipsoid is greater than 5 nm, and at least two of the semi axes of the ellipsoid are less than 30 nm. Other applications are also described.

Growing community of inventors

Haifa, Israel

Ella Fremder